Bolar's sustained release procainamide HCI
Executive Summary
Shipments of the first generic version of Park-Davis' Procan SR approved by FDA are underway. Bolar estimates a 5-10% share of Parke-Davis' $60 mil. market for its generic. The product is available in 250 mg, 500 mg and 750 mg tabs, each in bottles of 100, 500, and 1,000. Price to whslrs. for the biggest selling item, 500 mg 100s, is $20.43. Bolar said it expects approval for a generic of Ciba's Ismelin (guanthidine monosulfate) in January